Efficacy of LCQ908 on Cardiovascular Risk

Stopped The study was terminated based on interim analysis. See detailed description.

Conditions

• Coronary Artery Disease
• Hypertriglyceridemia

Interventions

• DRUG: pradigastat (LCQ908)
• DRUG: Placebo

Sponsor

Novartis Pharmaceuticals